# A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

> **NCT01561833** · PHASE1 · COMPLETED · sponsor: **Yale University** · enrollment: 12 (actual)

## Conditions studied

- T Cell Lymphoma

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01561833
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01561833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01561833, "A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01561833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*